NASDAQ: CRVS

Corvus Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

The consensus among 3 Wall Street analysts covering (NASDAQ: CRVS) stock is to Strong Buy CRVS stock.

Out of 3 analysts, 2 (66.67%) are recommending CRVS as a Strong Buy, 0 (0%) are recommending CRVS as a Buy, 1 (33.33%) are recommending CRVS as a Hold, 0 (0%) are recommending CRVS as a Sell, and 0 (0%) are recommending CRVS as a Strong Sell.

If you're new to stock investing, here's how to buy Corvus Pharmaceuticals stock.

(NASDAQ: CRVS) Corvus Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.56%.

Corvus Pharmaceuticals's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast CRVS's revenue for 2026 to be $98,077,164, with the lowest CRVS revenue forecast at $98,077,164, and the highest CRVS revenue forecast at $98,077,164. On average, 1 Wall Street analysts forecast CRVS's revenue for 2027 to be $516,866,654, with the lowest CRVS revenue forecast at $516,866,654, and the highest CRVS revenue forecast at $516,866,654.

In 2028, CRVS is forecast to generate $2,341,592,291 in revenue, with the lowest revenue forecast at $2,341,592,291 and the highest revenue forecast at $2,341,592,291.

According to 3 Wall Street analysts that have issued a 1 year CRVS price target, the average CRVS price target is $5.83, with the highest CRVS stock price forecast at $10.00 and the lowest CRVS stock price forecast at $3.50.

On average, Wall Street analysts predict that Corvus Pharmaceuticals's share price could reach $5.83 by Sep 7, 2024. The average Corvus Pharmaceuticals stock price prediction forecasts a potential upside of 294.12% from the current CRVS share price of $1.48.

(NASDAQ: CRVS) forecast ROE is N/A, which is considered weak.